Cancer cell & microenvironment最新文献_第7页

STAT5 activation in B-cell acute lymphoblastic leukemia: damned if you do, damned if you don’t b细胞急性淋巴细胞白血病中STAT5的激活:做也罢，不做也罢

Cancer cell & microenvironment Pub Date : 2016-02-22 DOI: 10.14800/ccm.1186

Zhengqi Wang, K. Bunting

{"title":"STAT5 activation in B-cell acute lymphoblastic leukemia: damned if you do, damned if you don’t","authors":"Zhengqi Wang, K. Bunting","doi":"10.14800/ccm.1186","DOIUrl":"https://doi.org/10.14800/ccm.1186","url":null,"abstract":"A significant role of the microenvironment in leukemogenesis is beginning to emerge. The leukemia cell microenvironment consists of not only the stromal and endothelial cell components but also the normal hematopoietic cells. Signal transducer and activator of transcription 5 (STAT5) is a latent transcription factor that is normally transiently activated by phosphorylation in response to microenvironmental signals. In hematopoietic cells, persistently activated STAT5 via aberrant receptor signaling, Janus kinases (JAKs), or intracellular tyrosine kinases is a bona fide driver of leukemogenesis. However, active IL-7/STAT5 signaling also protects the early B-cell genome by suppressing error-prone recombination and vulnerability to transformation. Along these lines, we have reported that lymphocyte development from transplanted STAT5-deficient fetal liver cells was blocked at the pre-pro-B-cell stage but when combined with transgenic Myc and Bcl-2 promoted faster initiation of B-ALL. Furthermore, inflammatory responses may also be involved in leukemia initiation in both pediatric and adult patients which are associated with decreased phosphorylation of STAT5. Likewise, additional targeted agents continue to be developed for precision medicine that prominently suppress signaling pathways. A common theme of all of these perturbations is potential risk for dysregulating hematopoiesis through general transcriptional modulation. Here we discuss the potential for STAT5 inhibition as a double edged sword in certain hematologic disorders, such as early B-cell lymphoblastic leukemias. Considering the rapid pace of understanding of the pre-leukemic decrease in poly-clonality that precedes leukemia, the functional changes associated with microenvironmental influences are thus of potential clinical significance.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83116434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Sugars and cell adhesion: the role of ST6GalNAc1 in prostate cancer progression 糖和细胞粘附:ST6GalNAc1在前列腺癌进展中的作用

Cancer cell & microenvironment Pub Date : 2016-02-08 DOI: 10.14800/CCM.1174

J. Munkley, D. Elliott

引用次数: 12

Complete response of severe idiopathic thrombocytopenic purpura after resection of bulky chromophobe renal cell carcinoma 大体积嫌色性肾细胞癌切除后严重特发性血小板减少性紫癜的完全缓解

Cancer cell & microenvironment Pub Date : 2016-01-18 DOI: 10.14800/CCM.1158

S. Maekawa, M. Nagata, H. Watanabe, Keina Nozaki, A. Takahashi, S. Minowada, Y. Homma

{"title":"Complete response of severe idiopathic thrombocytopenic purpura after resection of bulky chromophobe renal cell carcinoma","authors":"S. Maekawa, M. Nagata, H. Watanabe, Keina Nozaki, A. Takahashi, S. Minowada, Y. Homma","doi":"10.14800/CCM.1158","DOIUrl":"https://doi.org/10.14800/CCM.1158","url":null,"abstract":"Idiopathic thrombocytopenic purpura (ITP) associated with renal cell carcinoma (RCC) is relatively rare. In almost all of these case reports, patients affected with ITP developed differentially-involved cancer, because resection of cancer could not improve thrombocytopenia and the treatment of ITP needed to be continued after surgery. We report the case of a 48-year-old woman with massive renal cell carcinoma, measuring approximately 20 × 14 × 14 cm, who presented with severe thrombocytopenia: platelet count, 2000 cells/µl. After confirming normal bone-marrow, she received high-dose dexamethasone and intravenous gamma globulin, which rose the platelet count to normal levels. She then underwent left radical nephrectomy. The pathological examination revealed chromophobe RCC. After the resection, the platelet count was maintained within the normal range without any treatments. The current case is the first report of chromophobe RCC causative of severe ITP and the second case who achieved a sustained complete remission of ITP after cancer surgery alone; moreover our case is only one patient without other causes of ITP.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89583997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Opioids and cancer recurrence: A brief review of the literature 阿片类药物与癌症复发:文献综述

Cancer cell & microenvironment Pub Date : 2016-01-18 DOI: 10.14800/CCM.1159

J. Cata, D. Bugada, M. Marchesini, M. Gregori, M. Allegri

{"title":"Opioids and cancer recurrence: A brief review of the literature","authors":"J. Cata, D. Bugada, M. Marchesini, M. Gregori, M. Allegri","doi":"10.14800/CCM.1159","DOIUrl":"https://doi.org/10.14800/CCM.1159","url":null,"abstract":"Opioids are the most commonly used analgesics during and after cancer surgery and in patients with advanced malignancies who suffer from moderate to severe pain. It has been suggested that opioids can promote cancer progression through different mechanisms including a direct effect on malignant cells, stimulation of angiogenesis and immunosuppression. In contrast, other studies have shown that opioids have anticancer effects. The results of clinical studies remain controversial with some evidence indicating that a high expression of the mu opioid receptor is an independent factor of tumor progression while other studies indicate that the administration of opioids perioperatively is associated with cancer recurrence. Unfortunately, all those clinical studies are retrospective and suffer from significant confounding variables and biases. To date, there is no solid evidence to suggest the avoidance of opioids in cancer patients with moderate to significant with the goal of reducing cancer recurrence. Some authors have suggested the use of spinal administration of opioids in order to reduce systemic effects. Careful use of opioids should be advise to reduce side effects or hyperalgesia in relation to specific needs of the patients.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"95 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77318618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Multifunctional polymer vesicles for cancer stem cells-targeted drug/siRNA therapy 用于癌症干细胞靶向药物/siRNA治疗的多功能聚合物囊泡

Cancer cell & microenvironment Pub Date : 2016-01-11 DOI: 10.14800/CCM.1145

Qiuming Liu, Jianzhong Du

引用次数: 1

The role of miR-139-5p and miR-206 in non-small cell lung cancer (NSCLC) by targeting c-Met miR-139-5p和miR-206靶向c-Met在非小细胞肺癌(NSCLC)中的作用

Cancer cell & microenvironment Pub Date : 2016-01-11 DOI: 10.14800/CCM.1157

Chengcao Sun, Shu-Jun Li, Dejia Li

引用次数: 0

Immune dysfunction induced by myeloid-derived suppressor cells in lymphoma 淋巴瘤中髓源性抑制细胞诱导的免疫功能障碍

Cancer cell & microenvironment Pub Date : 2016-01-11 DOI: 10.14800/CCM.1111

Narges Seyfizadeh

引用次数: 4

Preoperative anemia, blood transfusion, and neutrophil-to-lymphocyte ratio in patients with stage i non-small cell lung cancer. i期非小细胞肺癌患者术前贫血、输血和中性粒细胞与淋巴细胞比值。

Cancer cell & microenvironment Pub Date : 2016-01-04 DOI: 10.14800/CCM.1116

J. Cata, C. Gutierrez, R. Mehran, D. Rice, J. Nates, Lei Feng, A. Rodríguez-Restrepo, F. Martínez, G. Mena, V. Gottumukkala

{"title":"Preoperative anemia, blood transfusion, and neutrophil-to-lymphocyte ratio in patients with stage i non-small cell lung cancer.","authors":"J. Cata, C. Gutierrez, R. Mehran, D. Rice, J. Nates, Lei Feng, A. Rodríguez-Restrepo, F. Martínez, G. Mena, V. Gottumukkala","doi":"10.14800/CCM.1116","DOIUrl":"https://doi.org/10.14800/CCM.1116","url":null,"abstract":"Perioperative and postoperative blood transfusions (BT), anemia and inflammation are associated with poor survivals in patients with non-small cell lung cancer (NSCLC). This study investigated the impact of perioperative BT on the survival of patients with NSCLC taking into account their preoperative inflammatory status and the presence of anemia. Demographic, perioperative, and survival data for 861 patients with stage I NSCLC was collected retrospectively. The primary endpoints of interest were recurrence-free (RFS) and overall survival (OS). Before and after propensity score matching, univariate and multivariable Cox proportional hazards models were used to evaluate the association between covariates and survival. A neutrophil-to-lymphocyte ratio (NLR) < 5 (hazard ratio [HR]: 0.58, 95% CI: 0.38-0.87; p = 0.009) and normal Hb concentration (HR: 0.72, 95% CI: 0.72; p = 0.022) were independently associated with longer RFS. The administration of blood perioperatively was associated with a trend towards worse RFS (HR: 0.69, 95% CI: 0.47-1.02; p = 0.066). The multivariate analysis also revealed that an NLR < 5 (HR: 0.48, 95% CI: 0.3-0.76; p = 0.001) and the absence of BT (HR: 0.63, 95% CI: 0.4-0.98; p = 0.04) were significantly associated with lower mortality risk. The propensity score matching analysis did not confirm the association between BT and poor RFS (HR: 0.63, 95% CI: 0.35-1.1; p = 0.108) and OS (HR: 0.52, 95% CI: 0.26-1.04; p = 0.06). Inflammation and anemia are common finding in patients with stage 1 NSCLC. After adjusting for these two important confounders, this study confirms that previous reports demonstrating an association between BT and poor survival after NSCLC surgery.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"17 1","pages":"e1116"},"PeriodicalIF":0.0,"publicationDate":"2016-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73494798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Sweet-P inhibition of glucocorticoid receptor β as a potential cancer therapy. 糖皮质激素受体β的Sweet-P抑制作为潜在的癌症治疗方法。

Cancer cell & microenvironment Pub Date : 2016-01-01 Epub Date: 2016-07-05

Assumpta C Nwaneri, Lucien McBeth, Terry D Hinds

{"title":"Sweet-P inhibition of glucocorticoid receptor β as a potential cancer therapy.","authors":"Assumpta C Nwaneri, Lucien McBeth, Terry D Hinds","doi":"","DOIUrl":"","url":null,"abstract":"The need for the development of new cancer therapies and push for the design of new targeting techniques is on the rise, and would be useful for cancers that are resistant to current drug treatments. The understanding of the genome has significantly advanced cancer therapy, as well as prevention and earlier detection. This research highlight discusses a potential new type of cancer-targeting molecule, Sweet-P, which is the first of its kind. Sweet-P specifically targets the microRNA-144 binding site in the 3' untranslated region (3' UTR) of the human glucocorticoid receptor β (GRβ), which has been demonstrated to increase expression. GRβ has been shown to be highly expressed in cells from solid tumors of uroepithelial carcinomas, gliomas, osteosarcomas, and hepatocellular carcinomas, as well as in liquid tumor cells from leukemia patients. In non-cancerous diseases, GRβ has been shown to be highly expressed in glucocorticoid-resistant asthma. These maladies brought the need for the development of the Sweet-P anti-GRβ molecule. Sweet-P was shown to repress the migration of bladder cancer cells, and may serve as a new therapeutic for GRβ-related diseases.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34602629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ascending the PEAK1 toward targeting TGFβ during cancer progression: Recent advances and future perspectives. 在癌症进展过程中瞄准 TGFβ 的 PEAK1 上升：最新进展与未来展望

Cancer cell & microenvironment Pub Date : 2016-01-01 Epub Date: 2016-01-28 DOI: 10.14800/ccm.1162

Farhana Runa, Yvess Adamian, Jonathan A Kelber

{"title":"Ascending the PEAK1 toward targeting TGFβ during cancer progression: Recent advances and future perspectives.","authors":"Farhana Runa, Yvess Adamian, Jonathan A Kelber","doi":"10.14800/ccm.1162","DOIUrl":"10.14800/ccm.1162","url":null,"abstract":"Cancer is the second leading cause of death in the United States. Mortality in patients with solid, epithelial-derived tumors strongly correlates with disease stage and the systemic metastatic load. In such cancers, notable morphological and molecular changes have been attributed to cells as they pass through a continuum of epithelial-mesenchymal transition (EMT) states and many of these changes are essential for metastasis. While cancer metastasis is a complex cascade that is regulated by cell-autonomous and microenvironmental influences, it is well-accepted that understanding and controlling metastatic disease is a viable method for increasing patient survival. In the past 5 years, the novel non-receptor tyrosine kinase PEAK1 has surfaced as a central regulator of tumor progression and metastasis in the context of solid, epithelial cancers. Here, we review this literature with a special focus on our recent work demonstrating that PEAK1 mediates non-canonical pro-tumorigenic TGFβ signaling and is an intracellular control point between tumor cells and their extracellular microenvironment. We conclude with a brief discussion of potential applications derived from our current understanding of PEAK1 biology.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/22/c1/nihms912436.PMC5790177.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35787491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0